ADAM17 and neoplasm: Interestingly, TACE activity is controlled by TIMP3, an endogenous inhibitor of TACE, and thus, TIMP3/TACE modulation is commonly observed in insulin resistance, diabetes, inflammation, and tumor angiogenesis [44, 45, 46].